aiwiki.page
English
Health / Medicine & Treatment / targeted-therapy

Targeted Therapy

Targeted therapy treats disease by acting on defined molecular mechanisms, using biological features to guide drug development and, often, treatment selection.

44 keywords1 linked from6 not yet writtenWritten by AI
CancerEnzymeTargeted Cancer…ChemotherapyPrecision Medici…HormoneCancer Immunothe…Monoclonal Antib…Targeted T…

Targeted therapy is treatment designed to act on a defined molecular component or biological process that contributes to disease. Its targets include abnormal signaling proteins, cell-surface receptors, inflammatory mediators, and mechanisms on which particular diseased cells depend. The term is used most prominently in cancer, where drugs may inhibit a growth-driving protein or deliver a toxic payload to cells bearing a particular antigen. It also applies to treatments for immune-mediated disorders and selected inherited diseases.

Targeted treatment links understanding of disease biology to therapeutic intervention. In some settings, identifying a specific molecular alteration is essential before a drug can be used effectively; in others, the target is sufficiently characteristic of a disease that individual molecular testing is unnecessary. Targeted does not mean exclusive to diseased tissue, free of adverse effects, or certain to work. Its effectiveness depends on the importance of the target, the drug’s properties, biological variation, and the capacity of disease processes to adapt.

Definition and boundaries

The defining feature of targeted therapy is a deliberate relationship between a treatment’s action and a molecular mechanism relevant to disease. A target may be an enzyme, receptor, structural protein, soluble signaling molecule, or molecular interaction. Treatment can block its activity, alter its function, remove it, or use its location to concentrate another therapeutic agent. The target need not itself be abnormal: a normal protein may become therapeutically important because diseased cells depend on it unusually strongly.

In oncology, targeted cancer therapy is conventionally distinguished from traditional chemotherapy. Many cytotoxic chemotherapies interfere with DNA replication or cell division and affect both malignant cells and normal rapidly dividing tissues. Targeted cancer drugs are instead developed around particular molecular dependencies or recognizable cellular features. This is a practical rather than absolute distinction. Chemotherapies also have molecular targets, while some targeted agents affect numerous proteins or damage normal proliferating cells.

Targeted therapy overlaps with, but is not identical to, precision medicine. Precision medicine is a broader approach that uses individual biological, clinical, and sometimes environmental information to classify disease and guide care. A molecularly matched cancer drug is one example. Targeted therapy can also be used without individual genomic selection, as occurs with many inflammatory disorders. Conversely, precision medicine includes decisions about screening, prognosis, and conventional drug dosing that do not involve targeted treatment.

Other treatment categories overlap with the term. Endocrine therapies act on hormone production or receptor signaling and are molecularly targeted in a broad sense, although they are often classified separately. Some cancer immunotherapies target precisely defined proteins but are principally categorized by their immune mechanism. A monoclonal antibody is a molecular format, not a synonym for targeted therapy: antibodies can block receptors, neutralize soluble molecules, recruit immune cells, or carry therapeutic payloads.

The terminology therefore depends partly on clinical context. Antimicrobial drugs can be highly selective for microbial molecules but are not ordinarily grouped under targeted therapy. Likewise, describing a medicine as targeted does not establish greater effectiveness or safety than an alternative. Clinical value depends on the disease, treatment setting, comparator, and measured outcomes rather than the label alone.

Historical development

Targeted therapy developed from the convergence of receptor pharmacology, molecular biology, and methods for producing selective medicines. Early twentieth-century ideas of selective toxicity, associated particularly with Paul Ehrlich, proposed that a chemical agent could act more strongly on a disease-causing organism or diseased tissue than on the host. These ideas preceded modern molecular techniques but helped establish the goal of achieving therapeutic discrimination.

Endocrine treatment provided an early demonstration that some cancers depend on a specific physiological signal. In 1941, Charles Huggins and Clarence Hodges reported relationships between androgen deprivation and changes in advanced prostate cancer. Later development of estrogen-receptor testing and drugs such as tamoxifen connected a measurable biological feature with treatment responsiveness in breast cancer. These approaches anticipated the modern pairing of a predictive marker with a mechanism-based medicine.

The discovery of the Philadelphia chromosome by Peter Nowell and David Hungerford in 1960 was another major step. Janet Rowley showed in 1973 that the abnormality involved a chromosomal translocation. Subsequent research identified the BCR::ABL1 fusion and its continuously active tyrosine kinase as central to chronic myeloid leukemia. Work by researchers including Brian Druker, Nicholas Lydon, and colleagues helped translate this biology into imatinib, approved in the United States in 2001. Its clinical activity demonstrated that inhibition of a dominant molecular driver could produce substantial disease control.

Antibody engineering opened a parallel route. Georges Köhler and César Milstein described hybridoma technology in 1975, enabling reproducible production of antibodies with defined specificity. Later engineering reduced the proportion of nonhuman antibody sequences and improved clinical usability. Rituximab, directed against CD20, received its first United States approval in 1997; trastuzumab, directed against HER2, followed in 1998. These agents established distinct ways to exploit cell-surface targets in lymphoma and breast cancer.

During the 2000s and 2010s, tumor sequencing, improved structural biology, and increasingly selective inhibitors expanded the field. Clinical classification began to incorporate molecular alterations alongside tissue of origin. The 2018 United States approval of larotrectinib for specified cancers with NTRK gene fusions illustrated a tumor-agnostic approach: eligibility depended on a shared molecular driver across several tumor types. Such approvals did not make anatomical diagnosis obsolete, but demonstrated that molecular mechanisms could sometimes organize treatment across conventional disease boundaries.

Molecular mechanisms and disease dependence

A useful therapeutic target must be more than detectable. It must contribute to disease, create a vulnerability, or provide a sufficiently selective route for drug delivery. In cancer, an alteration that drives malignant growth differs from a passenger alteration that accompanies the disease without being necessary for its maintenance. Establishing this distinction requires functional experiments, pharmacological evidence, and clinical observations; molecular association alone does not demonstrate therapeutic importance.

One important principle is oncogene addiction, in which a cancer remains unusually dependent on a particular growth-promoting pathway despite containing many other abnormalities. The BCR::ABL1 fusion in chronic myeloid leukemia is a well-characterized example. Some tumors with activating EGFR mutations or ALK rearrangements show analogous dependencies. Inhibiting the dominant signal can disrupt proliferation and survival sufficiently to cause tumor regression, although dependence may be incomplete or change during treatment.

Many targeted agents act on cell signaling. Receptor tyrosine kinases transmit extracellular information through pathways that regulate growth, survival, metabolism, and differentiation. Excessive activity may result from mutation, gene amplification, fusion, or abnormal production of a receptor’s ligand. Small molecules can inhibit an intracellular catalytic domain, whereas antibodies may block ligand binding, prevent receptor activation, or alter receptor trafficking. These mechanisms can converge on the same pathway while differing in tissue distribution and resistance patterns.

Another strategy exploits synthetic lethality: impairment of either of two cellular functions alone may be tolerated, while their combined loss causes cell death. PARP inhibitors use this principle in some tumors with defective homologous-recombination DNA repair, including cancers associated with certain BRCA1 or BRCA2 alterations. Their effects involve both inhibition of PARP activity and trapping of PARP proteins on DNA. Susceptibility depends on the wider repair context, not simply on the presence of any alteration in a DNA-repair gene.

Targets also exist outside malignant cells. Inhibition of vascular endothelial growth factor signaling can interfere with angiogenesis, the formation of blood vessels supporting tumor growth. Neutralizing an inflammatory cytokine can interrupt a disease-promoting interaction among immune and tissue cells. Correcting an abnormal ion-channel protein can restore a physiological function rather than kill a cell. These examples show that targeted therapy encompasses inhibition, functional correction, and selective delivery, with different expectations for how quickly and completely disease features may change.

Therapeutic formats and delivery

Small-molecule drugs are chemically defined compounds that can often enter cells and reach intracellular targets. Many inhibit protein kinases by binding at or near the ATP-binding site; others act at allosteric sites or form covalent bonds with specific amino-acid residues. Selectivity is relative rather than absolute. Closely related enzymes can share binding-site features, and a compound’s effects depend on both its molecular affinity and the concentrations achieved in different tissues.

Monoclonal antibodies usually act on extracellular or cell-surface targets because their size limits entry into intact cells. Their antigen-binding regions recognize a defined molecular feature, while other antibody regions may recruit immune effector functions. Trastuzumab interferes with HER2-associated biology and can promote immune-mediated killing. Rituximab binds CD20 on B cells and can produce B-cell depletion through several mechanisms. Antibodies against soluble cytokines instead reduce the availability of signals that sustain inflammatory disease.

An antibody–drug conjugate combines an antibody, a linker, and a cytotoxic payload. After binding a suitable cell-surface antigen, many such agents are internalized and release their payload during intracellular processing. Activity depends on antigen expression, internalization, linker stability, and payload properties. Some released payloads can cross cell membranes and damage neighboring cells, a “bystander effect” that may help overcome uneven antigen expression but also complicates selectivity.

A bispecific antibody recognizes two distinct binding targets. Some connect a tumor-associated antigen with CD3 on T cells, promoting immune-cell engagement with malignant cells. Others bind two receptors or two sites on a pathway-related structure. Targeted radiopharmaceuticals use an antibody or ligand to carry a radioactive isotope to selected tissues, combining molecular recognition with localized radiation exposure. These approaches sit at the boundaries of targeted therapy, immunotherapy, and nuclear medicine.

Delivery can be as important as binding. Oral absorption, protein binding, metabolism, and elimination determine drug exposure through pharmacokinetics. Large molecules may penetrate solid tumors unevenly, while the blood–brain barrier limits entry of many agents into the central nervous system. Some newer kinase inhibitors have been developed specifically for greater intracranial activity. A drug can therefore have strong activity against its purified target yet limited clinical effectiveness if it does not reach the relevant cells at an adequate, tolerable concentration.

Biomarkers and treatment selection

A biomarker is a measurable biological characteristic that provides information about a biological process or response. For targeted therapy, the most important distinction is between predictive and prognostic markers. A predictive marker identifies differences in the expected effect of a particular treatment. A prognostic marker indicates likely disease outcome regardless of that treatment. The same characteristic can have both roles, but an association with poor prognosis does not by itself establish that a matching drug will help.

Testing methods depend on the target. Immunohistochemistry measures protein expression and distribution in tissue. In situ hybridization can identify gene amplification or rearrangement. Polymerase chain reaction assays detect selected nucleic-acid sequences, while next-generation sequencing can examine many genes simultaneously. DNA-based and RNA-based tests provide different information; RNA analysis can be particularly useful for demonstrating expressed gene fusions. No single technique detects every clinically relevant alteration equally well.

A companion diagnostic is a test whose information is essential to the safe and effective use of a corresponding therapeutic product under a particular regulatory framework. HER2 assessment for selected breast-cancer treatments and EGFR mutation testing for certain lung-cancer drugs are established examples. A biomarker result must be interpreted at the level of the specific alteration and indication. Different mutations in the same gene may confer sensitivity, resistance, or no established therapeutic implication.

Tissue obtained through biopsy remains important because it supports both histological classification and molecular characterization. Blood-based assays can detect circulating tumor DNA released into plasma. Such assays may identify actionable alterations or emerging resistance without another tissue procedure. However, tumors vary in how much DNA they shed, and a negative blood result does not necessarily exclude an alteration. Some findings may arise from nonmalignant blood-cell clones rather than the tumor, creating an additional interpretive issue.

Testing also samples a disease that may vary across space and time. One lesion may differ from another, and a specimen collected before several lines of treatment may not represent current biology. Analytical quality, specimen handling, tumor content, assay coverage, and reporting thresholds all influence results. Inherited and tumor-acquired variants must also be distinguished: tumor testing can reveal findings that warrant separate assessment of hereditary risk, but it does not automatically establish that an alteration is present throughout the person’s body.

Established applications in cancer

Hematological malignancies provide some of the clearest examples of target-dependent treatment. BCR::ABL1 inhibitors have transformed the management of chronic myeloid leukemia, with molecular measurements of fusion transcripts supporting assessment of response. Other targeted treatments act on BTK-dependent signaling, the anti-apoptotic protein BCL2, or mutated FLT3 and IDH proteins in defined blood cancers. These drugs illustrate different therapeutic strategies: interrupting survival signals, restoring susceptibility to programmed cell death, or altering abnormal cellular metabolism and differentiation.

In breast cancer, HER2 amplification or overexpression identifies a group for which HER2-directed antibodies, kinase inhibitors, and antibody–drug conjugates have established roles. These medicines are used in different combinations and disease settings, including treatment intended to reduce recurrence after local therapy and treatment for metastatic disease. Hormone-receptor-positive disease provides another model, in which inhibition of estrogen signaling can be combined with agents acting on cell-cycle control or other growth pathways.

Molecular testing has also reshaped treatment of selected forms of lung cancer. Activating EGFR mutations, ALK or ROS1 rearrangements, and other defined alterations can identify susceptibility to particular inhibitors. These categories do not encompass all lung cancers, and not every alteration in a listed gene has the same significance. Treatment development has also addressed brain metastases, where adequate central-nervous-system exposure can materially affect disease control.

In other solid tumors, the relationship between target and tissue context is especially apparent. BRAF inhibition has established activity in selected BRAF-mutated melanomas, commonly with MEK inhibition. In BRAF V600E-mutated colorectal cancer, feedback activation of EGFR helps explain why BRAF inhibition alone is relatively ineffective and why combinations that address this feedback are used. Gastrointestinal stromal tumors provide another example: many depend on KIT or PDGFRA signaling, but sensitivity varies substantially among molecular subtypes.

Tumor-agnostic treatments apply to specified molecular findings across more than one anatomical cancer type. NTRK-fusion inhibitors are a prominent example, but such fusions are uncommon in many common adult cancers. Even when a drug has a broad molecular indication, evidence may be uneven across rare subgroups. The presence of a nominal target is therefore only one part of treatment classification; prior therapy, disease stage, accompanying alterations, and the evidence supporting the exact clinical setting remain important determinants of established use.

Applications beyond oncology

In immune-mediated disease, targeted therapy often acts on communication between cells rather than on a disease-specific genetic mutation. Tumor necrosis factor inhibitors reduce signaling through a cytokine involved in several inflammatory pathways. They have established uses in conditions including rheumatoid arthritis and forms of inflammatory bowel disease. Their activity across several diagnoses reflects shared inflammatory mechanisms, while differences in effectiveness among diseases show that apparently related pathways are not interchangeable.

Other agents target interleukins, their receptors, or intracellular signaling enzymes. IL-17 and IL-23 pathway inhibitors have important roles in psoriasis. JAK inhibitors alter signaling downstream of multiple cytokine receptors and are used in selected inflammatory and hematological conditions. Abatacept, a fusion protein, modifies T-cell costimulation by binding CD80 and CD86. These examples differ in selectivity: blocking one extracellular cytokine does not have the same biological reach as inhibiting an intracellular enzyme used by several signaling systems.

In allergic disease, targeted medicines can act on immunoglobulin E or pathways associated with type 2 inflammation. Omalizumab binds free IgE and reduces its availability to participate in allergic activation. Other biologics target IL-5, the IL-5 receptor, or the shared receptor component used by IL-4 and IL-13. In selected forms of asthma, treatment classification uses clinical features and biomarkers such as eosinophil counts because the same outward diagnosis can arise from different inflammatory patterns.

Cystic fibrosis provides a different model: restoration of a defective protein’s function. CFTR modulators act on the cystic fibrosis transmembrane conductance regulator. Potentiators increase the opening probability of channels that reach the cell surface, whereas correctors improve aspects of protein processing and trafficking. Ivacaftor, first approved in the United States in 2012, established genotype-linked treatment for selected CFTR variants. Later combinations expanded the range of responsive genotypes, although not all disease-causing variants are amenable to currently established modulation.

Targeted treatment outside cancer also includes manipulation of complement pathways and reduction of disease-causing proteins. Eculizumab binds complement component C5 and inhibits terminal complement activation in specified disorders. RNA-based medicines can reduce production of selected proteins by altering RNA processing or promoting RNA degradation. These approaches illustrate why targeted therapy is broader than cytotoxicity: a treatment may suppress an excessive immune pathway, restore channel activity, or lower a harmful protein while leaving the treated cells alive.

Resistance and biological adaptation

Resistance can be present before treatment or emerge after an initial response. Primary resistance means that an expected therapeutic effect is absent or limited from the outset. Acquired resistance develops when a previously responsive disease progresses during treatment. These categories describe clinical behavior rather than a single mechanism. Apparent resistance may reflect an incorrect biological assumption, inadequate drug exposure, mixed disease populations, or an adaptive change in the target or surrounding network.

One common mechanism is alteration of the drug-binding site. The target can remain biologically active while becoming less susceptible to inhibition. EGFR T790M was a major mechanism of resistance to earlier-generation EGFR inhibitors; later drugs were developed with activity against that alteration. Resistance to those later agents can involve other changes, including EGFR C797S in some cases. In chronic myeloid leukemia, BCR::ABL1 kinase-domain mutations can similarly influence sensitivity to different inhibitors.

A disease can also bypass the inhibited target. Amplification or activation of another receptor may restore downstream signaling even when the original drug continues to bind successfully. MET amplification is one recognized route of resistance in EGFR-driven lung cancer. Alternatively, a tumor may restore a cellular function that treatment had exploited as defective. Some cancers exposed to PARP inhibitors acquire changes that restore aspects of homologous-recombination repair, reducing the vulnerability on which treatment depended.

Resistance need not involve a new target mutation. Cancer cells can adopt alternative transcriptional states, alter drug transport, change their interactions with surrounding tissue, or undergo lineage transformation. Some EGFR-mutated lung cancers, for example, can develop small-cell histological features while retaining the original EGFR alteration. Spatial heterogeneity adds another layer: a drug may suppress one metastatic site while another progresses because its cellular composition or drug exposure differs.

Treatment strategies developed to address resistance include sequential inhibitors, combinations targeting parallel pathways, and agents with improved tissue penetration. Combination treatment can reduce the chance that one escape mechanism will suffice, but it may also increase toxicity and select for more complex resistance. Repeat molecular assessment and clinical studies of resistant disease have therefore become integral to drug development. Detection of a resistance-associated alteration is not itself proof that a proposed replacement treatment will produce meaningful clinical benefit.

Safety, exposure, and treatment burden

Targeted medicines can cause substantial adverse effects because their targets frequently participate in normal physiology. This is described as on-target toxicity when harm follows from inhibiting the intended target in healthy tissues. EGFR inhibition can disturb skin and intestinal epithelial function, producing rash and diarrhea. Inhibition of vascular endothelial growth factor signaling can affect vascular homeostasis and is associated with hypertension, proteinuria, bleeding, and other complications in relevant treatment settings.

Other adverse effects arise from interactions with unintended targets or from the therapeutic format itself. An antibody–drug conjugate can cause toxicities related to its payload, linker behavior, tissue distribution, or target expression in normal tissues. Different products can therefore have substantially different safety profiles even when directed against the same antigen. Some targeted medicines are associated with interstitial lung disease, liver injury, cardiac dysfunction, or changes in electrical conduction, but these effects are not uniform across the category.

Immune-targeted agents have mechanism-specific risks. Depleting B cells or blocking inflammatory cytokines can impair protective immune functions and increase susceptibility to selected infections. T-cell-engaging treatments can trigger cytokine release syndrome, reflecting widespread immune activation rather than conventional direct cytotoxic injury. The safety consequences of inhibiting an immune pathway depend on that pathway’s role in host defense, the treatment combination, and characteristics of the treated population.

Drug exposure further shapes safety. Oral targeted agents can interact with medicines that inhibit or induce drug-metabolizing enzymes, and some have absorption affected by gastric acidity or food. Reduced organ function can alter clearance. A pharmacokinetic interaction may increase toxicity or reduce effectiveness without changing the molecular target. Pharmacogenomics can help explain selected differences in drug handling, but genomic information does not account for all variability in exposure or response.

Treatment burden also includes duration, route of administration, laboratory surveillance, and effects on quality of life. Some therapies are given for a fixed period, whereas others continue until progression or unacceptable toxicity. Long-term administration can create cumulative burdens even when each individual adverse effect is manageable. Safety assessment therefore includes treatment discontinuation, dose modification, delayed effects, and patient-reported outcomes, rather than relying only on whether severe toxicity occurred during the earliest treatment cycles.

Clinical evidence, regulation, and access

Development of a targeted medicine links target validation, drug discovery, assay development, and clinical evaluation. Laboratory studies establish whether manipulating a target changes disease-relevant behavior, but experimental models cannot fully reproduce human disease. Early clinical trials examine safety, exposure, and signs of biological activity. Demonstrating target engagement—evidence that the drug interacts with its intended target in the body—supports the mechanism, but does not alone establish that patients live longer or feel better.

Biomarker-based development can use several trial structures. An enrichment design enrolls participants whose disease has a selected marker. A basket trial examines one molecularly defined treatment across several disease types, while an umbrella trial evaluates multiple targeted strategies within one disease category. These designs can efficiently study uncommon subgroups, but small samples and biological differences among groups complicate interpretation. A randomized controlled trial remains especially valuable when comparative benefit cannot be reliably inferred from response rates alone.

Cancer studies commonly measure objective response, duration of response, progression-free survival, and overall survival. Tumor shrinkage can be persuasive in settings where substantial spontaneous regression is unusual, but response does not necessarily predict longer survival or better functioning. Progression-free survival can be influenced by assessment schedules and subsequent treatment patterns. The role of a surrogate endpoint depends on evidence connecting it to outcomes that matter directly to patients in the relevant disease and treatment context.

Regulatory pathways differ across jurisdictions. Some permit earlier authorization on the basis of promising intermediate outcomes, with further studies required to clarify benefit. Subsequent evidence can lead to expansion, restriction, or withdrawal of an indication. Approval is specific to a product, disease setting, biomarker definition, and often prior treatment history; it does not validate all uses of that drug or every theoretically related molecular finding.

Access depends on more than whether a drug exists. Molecular pathology capacity, specimen transport, testing turnaround, specialist services, reimbursement, and medicine supply all affect delivery through a health system. Antibody biosimilars and generic small molecules can alter costs, but testing and service requirements remain important. Evaluations of value may consider survival, toxicity, quality of life, and quality-adjusted life years, alongside budget impact. Differences in access to validated testing can create disparities before a treatment decision is even reached, making diagnostic infrastructure part of the practical availability of targeted therapy.